As acquisition of spliceosome gene mutations result to be the initiating events in clonal hematopoiesis, the use of spliceosomal modulation to induce synthetic lethality in splicing factor mutant hematological malignancies, currently being tested in an early phase clinical trial, is quite exciting [150]. This evidence concerns the gene SLU7 and hematologic disorder.